

Market Outlook

Nifty 50 ended the day at 24924 driven by a surprise India-Pakistan ceasefire, easing global tensions, and robust foreign inflows. The India VIX ended at 18.39. The Advance-Decline Ratio is 24, indicating Bullish trend. Derivatives data suggests Sideways to Positive sentiments in the market for the coming sessions, with significant increase in both CALL and PUT options OI data.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	24924.70	3.81
SENSEX	82429.90	3.74
BANKNIFTY	55382.85	3.33
SMALLCAP	16767.30	4.23

FII's STATISTICS


FII's F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	1211.29	-0.83%
Index Options	7771	16.70%
Stock Futures	7074.31	0.82%
Stock Options	-923.07	3.75%

FII's & DII's Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	1246.48	9104	11839
DII	1448.37	15189	43417

FII's Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
ETERNAL	16413459	6.54	30.07
RELIANCE	6995270	-9.02	-21.91
INFY	6667113	-8.25	153.93
ICICIBANK	6650816	-5.74	-26.43
HDFCBANK	6484427	-5.03	8.32
ONGC	5799200	8.68	1.7
ITC	5115462	-7.12	-2.37
AXISBANK	4930706	-3.28	41.58
SUNPHARMA	4686689	-7.84	702.56
NTPC	4634349	-2.59	-29.53


NIFTY

Nifty	25044.10
OI (In contracts)	168587
CHANGE IN OI (%)	0.19
PRICE CHANGE (%)	4.07
IMPLICATION	LONG BUILDUP

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Build Up

Symbol	Price	Price %	OI	OI %
RAMCOCEM	960.4	2.0	7087300	30.0
YESBANK	20.08	9.9	56147000	14.7
TATATECH	705.1	5.5	12814900	8.8
INDHOTEL	773.3	7.1	24128000	8.2
PATANJALI	1830.4	4.0	3926700	8.0


BANKNIFTY

Banknifty	55599.20
OI (In lakhs)	63839
CHANGE IN OI (%)	6.35
PRICE CHANGE (%)	3.48
IMPLICATION	LONG BUILDUP

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Build Up

Symbol	Price	Price %	OI	OI %
UPL	675.85	-0.4	30366905	7.7
SUNPHARMA	1695.3	-3.1	16330650	6.1
INDUSINDBK	789.95	-3.5	36999500	3.5
SOLARINDS	13359	-1.1	404100	2.8
CHAMBLFERT	692.1	-0.0	7849850	2.7

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
INDIGO	2757750	2025600	1.36
AARTIIND	9728600	7285000	1.34
NCC	7125775	5818450	1.22
BHEL	28300125	23701125	1.19
JSL	1308975	1107475	1.18
BSE	3902875	3381750	1.15
PERSISTENT	991700	895900	1.11
ZYDUSLIFE	3734100	3448800	1.08
IIFL	5418800	5077800	1.07
MANAPPURAM	31590000	29580000	1.07

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
SYNGENE	5111000	15310000	0.33
NTPC	19348500	50097000	0.39
ULTRACEMCO	713700	1764200	0.4
IDEA	560186825	1372546750	0.41
VBL	6782275	16211125	0.42
UPL	7485020	17533700	0.43
HDFCLIFE	8065200	18173100	0.44
IRFC	28116525	60257075	0.47
ACC	2891100	6059100	0.48
SBILIFE	2964750	6001125	0.49

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2477	2518	2403	2362	2288
ADANIPTS	1382	1396	1365	1352	1335
APOLLOHOSP	7031	7098	6903	6836	6709
ASIANPAINT	2387	2413	2362	2337	2311
AXISBANK	1223	1238	1197	1182	1155
BAJAJ-AUTO	8181	8280	7990	7891	7700
BAJAJFINSV	2081	2101	2047	2027	1992
BAJFINANCE	9148	9229	8999	8918	8769
BEL	328	331	322	319	313
BHARTIARTL	1895	1909	1874	1860	1840
CIPLA	1536	1554	1500	1481	1445
COALINDIA	401	405	395	391	384
DRREDDY	1224	1249	1183	1158	1118
EICHERMOT	5599	5649	5516	5466	5383
ETERNAL	244	247	238	235	229
GRASIM	2794	2835	2733	2693	2631
HCLTECH	1704	1733	1650	1621	1567
HDFCBANK	1987	2006	1952	1933	1897
HDFCLIFE	744	750	734	728	718
HEROMO-TOCO	4031	4070	3970	3932	3870
HINDALCO	662	669	650	644	632
HINDUNILVR	2412	2428	2382	2366	2336
ICICIBANK	1472	1490	1439	1422	1389
INDUSINDBK	823	855	805	772	754
INFY	1671	1710	1598	1560	1487

SYMBOL	R1	R2	PP	S1	S2
ITC	439	443	433	430	423
JIOFIN	268	272	261	257	251
JSWSTEEL	1024	1038	998	984	958
KOTAKBANK	2174	2191	2152	2135	2113
LT	3644	3688	3567	3522	3445
M&M	3145	3174	3093	3065	3013
MARUTI	12686	12764	12545	12467	12326
NESTLEIND	2410	2428	2375	2356	2321
NTPC	355	359	347	343	335
ONGC	249	253	242	239	232
POWERGRID	313	316	310	307	304
RELIANCE	1456	1470	1430	1415	1389
SBILIFE	1770	1782	1750	1738	1718
SBIN	800	810	790	780	770
SHRIRAMFIN	662	675	636	622	596
SUNPHARMA	1736	1777	1681	1640	1585
TATACONSUM	1163	1176	1143	1129	1109
TATAMOTORS	734	744	723	713	702
TATASTEEL	155	158	150	147	142
TCS	3681	3726	3598	3554	3471
TECHM	1600	1621	1560	1538	1498
TITAN	3603	3630	3572	3545	3513
TRENT	5579	5676	5412	5315	5148
ULTRACEMCO	11864	11946	11731	11649	11516
WIPRO	264	268	254	249	240

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results

Name	Email ID	Designation
Vishvajeet Singh	vishvajeet.singh1@religare.com	Research Analyst